Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLUESTAR: AZD8205 alone and in combinations for advanced solid tumors
jRCT2031210585Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2022
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of puxitatug samrotecan, rilvegostomig, saruparib and palacaparib in biliary cancer, ovarian cancer, breast cancer and 2 more (6 arms), sponsored by AstraZeneca. Primary endpoints: Adverse events, Serious adverse events and 2 more. Started Jan 2022; status: recruiting.
02
Drugs
puxitatug samrotecanrilvegostomigsaruparibpalacaparib
03
Conditions
biliary cancerovarian cancerbreast cancerendometrial cancer (EC)Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on jRCT2031210585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210585.